3 days ago
RYTM
AnalystsDerek ArchilaDerek Archila's Stock Forecasts
AnalystsDerek Archila
Analyst Ranking
Top 3%
#144 out of 4937 analysts
Average Return
+25.19%
Win Rate
54%70 out of 129
Risk vs Reward
Poor
Good
Derek Archila's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cabaletta Bio IncCABA | +1,563.62% | $0.87 | $14.54 | 2022-09-14 - 2023-09-13 | Strong Buy |
Prometheus Biosciences IncRXDX | +604.58% | $27.52 | $193.90 | 2022-05-13 - 2023-05-12 | Strong Buy |
Prometheus Biosciences IncRXDX | +294.01% | $50.74 | $199.92 | 2022-08-29 - 2023-06-15 | Strong Buy |
Prometheus Biosciences IncRXDX | +185.97% | $33.50 | $95.80 | 2021-12-08 - 2022-12-07 | Strong Buy |
Atyr Pharma IncATYR | +183.42% | $1.87 | $5.30 | 2024-10-04 - 2025-07-11 | Strong Buy |
Derek Archila Analyst Color
Get additional color on Derek Archila's coverage of popular stocks
23 days ago
ATYR
3 months ago
RYTM
4 months ago
ARGX
7 months ago
ARGX
7 months ago
CCCC
7 months ago
KYMR
8 months ago
ARGX
9 months ago
SLRN
10 months ago
ASND
a year ago
ARGX
a year ago
ARGX
a year ago
ANNX
a year ago
CABA
a year ago
ASND
a year ago
ZYME
2 years ago
MOR
2 years ago
IMVT
2 years ago
CABA
2 years ago
APLS
2 years ago
ARGX
2 years ago
IMVT
2 years ago
MORF
3 years ago
CABA
3 years ago
ASND
Derek Archila's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Rhythm Pharmaceuticals IncRYTM | 6 | Strong Buy | $129.00 | +48.79% | Maintains | 3 days ago |
Kymera Therapeutics IncKYMR | 8 | Strong Buy | $53.00 | +19.15% | Maintains | 17 days ago |
Atyr Pharma IncATYR | 2 | Strong Buy | $25.00 | +371.70% | Maintains | 23 days ago |
Blueprint Medicines CorpBPMC | 8 | Hold | $129.00 | -0.23% | Downgrades | a month ago |
Apellis Pharmaceuticals IncAPLS | 11 | Hold | $29.00 | +49.18% | Maintains | a month ago |
Septerna IncSEPN | 4 | Hold | $18.00 | +53.45% | Maintains | 2 months ago |
Arvinas IncARVN | 6 | Strong Buy | $19.00 | +143.90% | Maintains | 2 months ago |
Incyte CorpINCY | 7 | Hold | $59.00 | -13.98% | Maintains | 2 months ago |
Nurix Therapeutics IncNRIX | 5 | Strong Buy | $25.00 | +100.96% | Maintains | 3 months ago |
Cabaletta Bio IncCABA | 10 | Hold | $3.00 | +72.41% | Maintains | 3 months ago |
Monte Rosa Therapeutics IncGLUE | 5 | Hold | $10.00 | +93.80% | Maintains | 4 months ago |
Q32 Bio IncQTTB | 2 | Hold | $15.00 | +463.91% | Maintains | 4 months ago |
Argenx SeARGX | 11 | Strong Buy | $741.00 | +32.26% | Maintains | 4 months ago |
Exelixis IncEXEL | 3 | Hold | $36.00 | -19.75% | Downgrades | 5 months ago |
Anaptysbio IncANAB | 3 | Strong Buy | $51.00 | +94.66% | Maintains | 5 months ago |
Zentalis Pharmaceuticals IncZNTL | 4 | Hold | $6.00 | +351.13% | Maintains | 5 months ago |
Zymeworks IncZYME | 5 | Hold | $14.00 | +4.95% | Maintains | 7 months ago |
Kezar Life Sciences IncKZR | 10 | Hold | $9.00 | +99.56% | Maintains | 7 months ago |
Immunovant IncIMVT | 9 | Strong Buy | $45.00 | +148.21% | Maintains | 7 months ago |
C4 Therapeutics IncCCCC | 5 | Strong Buy | $12.00 | +438.12% | Upgrades | 7 months ago |
Viridian Therapeutics IncVRDN | 1 | Hold | $27.00 | +58.45% | Downgrades | 7 months ago |
Acelyrin IncSLRN | 5 | Strong Buy | $13.00 | +472.69% | Maintains | 7 months ago |
Kyverna Therapeutics IncKYTX | 1 | Strong Buy | $24.00 | +495.53% | Maintains | 8 months ago |
Ascendis Pharma AASND | 12 | Strong Buy | $289.00 | +65.18% | Maintains | 10 months ago |
Ventyx Biosciences IncVTYX | 4 | Strong Buy | $11.00 | +301.46% | Maintains | a year ago |
Celldex Therapeutics IncCLDX | 3 | Hold | $37.00 | +61.50% | Maintains | a year ago |
Annexon IncANNX | 3 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Morphosys AgMOR | 4 | Hold | $18.25 | N/A | Downgrades | a year ago |
Dice Therapeutics IncDICE | 2 | Hold | $48.00 | N/A | Maintains | 2 years ago |
Morphic Holding IncMORF | 5 | Strong Buy | $80.00 | N/A | Maintains | 2 years ago |
Horizon Therapeutics Public Ltd CoHZNP | 2 | Hold | $116.50 | N/A | Downgrades | 3 years ago |
Prometheus Biosciences IncRXDX | 4 | Strong Buy | $71.00 | N/A | Maintains | 3 years ago |
Arena Pharmaceuticals IncARNA | 1 | Strong Buy | $71.00 | N/A | Initiates Coverage On | 4 years ago |
Esperion Therapeutics IncESPR | 1 | Hold | $20.00 | N/A | Downgrades | 4 years ago |
Lumos Pharma IncLUMO | 1 | Strong Buy | $24.00 | N/A | Upgrades | 4 years ago |
Momenta Pharmaceuticals IncMNTA | 2 | Hold | $52.50 | N/A | Downgrades | 5 years ago |
Principia Biopharma IncPRNB | 1 | Hold | $100.00 | N/A | Downgrades | 5 years ago |
Inventiva SaIVA | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 5 years ago |
Genfit SaGNFT | 1 | Strong Buy | N/A | N/A | Upgrades | 5 years ago |
Galapagos NvGLPG | 1 | Hold | $193.00 | N/A | Downgrades | 5 years ago |
Viela Bio IncVIE | 1 | Hold | $58.00 | N/A | Initiates Coverage On | 5 years ago |
Cymabay Therapeutics IncCBAY | 1 | Strong Buy | $8.00 | N/A | Upgrades | 5 years ago |
Oneok IncOKE | 1 | Strong Buy | $41.00 | N/A | Reiterates | 5 years ago |
Amarin Corp PLCAMRN | 3 | Hold | $160.00 | N/A | Maintains | 5 years ago |
Ngm Biopharmaceuticals IncNGM | 1 | Strong Buy | $32.00 | N/A | Maintains | 5 years ago |
Dbv Technologies SaDBVT | 3 | Hold | $60.00 | N/A | Downgrades | 5 years ago |
Vanda Pharmaceuticals IncVNDA | 4 | Hold | $29.00 | N/A | Downgrades | 7 years ago |
Heron Therapeutics IncHRTX | 2 | Buy | $50.00 | N/A | Maintains | 7 years ago |
Urogen Pharma LtdURGN | 1 | Buy | $51.00 | N/A | Maintains | 8 years ago |
Perrigo Co PLCPRGO | 1 | Buy | $88.00 | N/A | Initiates Coverage On | 8 years ago |
Pacira Biosciences IncPCRX | 1 | Hold | N/A | N/A | Initiates Coverage On | 8 years ago |
Zynerba Pharmaceuticals IncZYNE | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Teva Pharmaceutical Industries LtdTEVA | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.